The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
- Resource Type
- Article
- Source
- The Lancet; April 2021, Vol. 397 Issue: 10282 p1363-1374, 12p
- Subject
- Language
- ISSN
- 01406736; 1474547X